Health ❯ Pharmaceuticals ❯ Drug Development

Respiratory Diseases

Chronic Obstructive Pulmonary Disease (COPD) Nerandomilast

GSK Closes $12 Billion Licensing Pact for Hengrui’s COPD Therapy and 11 Preclinical Assets

The pact underscores Chinese biotech’s rapid rise in global licensing, with Hengrui leading Phase I trials for the COPD asset before GSK’s later-stage development.

10 ARTICLES

5mo ago

Merck to Acquire Verona Pharma in $10 Billion Deal for Ohtuvayre COPD Therapy